Aripiprazole Mylan Pharma 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0023 
B.II.d.1.z - Change in the specification parameters 
16/02/2024 
SmPC and PL 
and/or limits of the finished product - Other variation 
N/0022 
Minor change in labelling or package leaflet not 
06/09/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
WS/2306 
This was an application for a variation following a 
15/12/2022 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0021 
C.I.2.a - Change in the SPC, Labelling or PL of a 
12/09/2022 
09/10/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0019 
B.III.1.a.2 - Submission of a new/updated or 
22/06/2022 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
N/0018 
Minor change in labelling or package leaflet not 
03/05/2022 
09/10/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
T/0017 
Transfer of Marketing Authorisation 
24/09/2021 
19/11/2021 
SmPC, 
Labelling and 
PL 
IB/0016/G 
This was an application for a group of variations. 
08/09/2021 
19/11/2021 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0015 
B.III.1.a.3 - Submission of a new/updated or 
26/10/2020 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IB/0014 
C.I.2.a - Change in the SPC, Labelling or PL of a 
11/06/2020 
18/11/2021 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
R/0013 
Renewal of the marketing authorisation. 
12/12/2019 
25/02/2020 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II/0012 
B.I.z - Quality change - Active substance - Other 
07/11/2019 
n/a 
variation 
II and PL 
the CHMP considered that the benefit-risk balance of 
Aripiprazole Mylan Pharma in the approved indication 
remains favourable and therefore recommended the 
renewal of the marketing authorisation with unlimited 
validity. 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0011 
C.I.2.a - Change in the SPC, Labelling or PL of a 
13/06/2019 
25/02/2020 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
N/0010 
Minor change in labelling or package leaflet not 
13/03/2019 
25/02/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0009 
C.I.2.a - Change in the SPC, Labelling or PL of a 
02/02/2018 
14/02/2019 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IB/0008 
C.I.11.z - Introduction of, or change(s) to, the 
16/06/2017 
26/07/2017 
Annex II and 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
PL 
IB/0007 
C.I.2.a - Change in the SPC, Labelling or PL of a 
15/12/2016 
26/07/2017 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IB/0006 
C.I.2.a - Change in the SPC, Labelling or PL of a 
10/08/2016 
26/07/2017 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
Labelling and 
PL 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
T/0005 
Marketing Authorisation Transfer from Pharmathen 
27/06/2016 
01/08/2016 
SmPC, 
S.A to Mylan S.A.S. 
Transfer of Marketing Authorisation 
Labelling and 
PL 
IAIN/0004 
A.2.a - Administrative change - Change in the 
03/06/2016 
01/08/2016 
SmPC, 
(invented) name of the medicinal product for CAPs 
Labelling and 
PL 
IB/0001/G 
This was an application for a group of variations. 
23/03/2016 
01/08/2016 
SmPC, Annex 
II, Labelling 
and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0003 
B.II.b.1.a - Replacement or addition of a 
16/03/2016 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0002/G 
This was an application for a group of variations. 
16/03/2016 
01/08/2016 
SmPC, 
Labelling and 
PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
Page 6/7 
 
 
 
 
 
 
 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Page 7/7 
 
 
 
 
 
 
 
